






Supplementary figure 1. The HE stain of acute and chronic drug liver pathology. The hepatic pathological changes that were administrated for 1 day and 21 days respectively to assess the acute and the chronic liver damage.



Supplementary figure 2. The sequence pictures of the combination of quercetin and triptolide in 48 hours in the same point by Live cell workstation(IncuCyteZOOM 2015A).

TP100nmol/L+QU100μmol/L: 100nmol/L triptolide was combined with 100μmol/L quercetin; TP50nmol/L+QU100μmol/L: 50nmol/L triptolide was combined with 100μmol/L quercetin; TP100nmol/L+QU 0μmol/L: 100nmol/L triptolide was combined with 0 μmol/L quercetin.




Supplementary figure 3. The sequence pictures of the combination of quercetin and triptolide in 48 hours in the same point by Live cell workstation(IncuCyteZOOM 2015A).

TP25nmol/L+ QU75μmol/L: 25nmol/L triptolide was combined with 75μmol/L quercetin;


TP25nmol/L+ QU50μmol/L: 25nmol/L triptolide was combined with 50μmol/L quercetin;

TP25nmol/L+ QU25μmol/L: 25nmol/L triptolide was combined with 25μmol/L quercetin;

TP25nmol/L+ QU12.5μmol/L: 25nmol/L triptolide was combined with 12.5μmol/L quercetin.



Supplementary figure 4. CompuSyn method is used to calculate the combination index for each drug combinations.



Supplementary figure 5. The apoptosis-related protein in different groups. A) Western blots showing the levels of Bcl-2, Bax, P53, caspase-3 and cleaved caspase-3 proteins; B,C,E,F,G) showed expression of each protein normalized by β -actin according to grey value after 48 hours; D) showed the bax/bcl-2 ratio; H) showed expression of cleaved caspase-3 normalized by β -actin according to grey value after 24 hours.

Supplementary table 1. The detail administration for the intervention style and the grouping

Group	Administer first	Administer after 20 minutes
Control group	2% DMSO physiological saline (body weight $\times$ 10ul)	0.1% DMSO physiological saline (body weight $\times$ 10ul)
Quercetin group	2% DMSO quercetin (4mg/ml), each given 40mg/kg	0.1% DMSO physiological saline (body weight $\times$ 10ul)
Triptolide group	2% DMSO physiological saline (body weight $\times$ 10ul)	0.1% DMSO of Triptolide A (50ug/mL), given 500ug/kg per animal
Triptolide combined Quercetin group	2% DMSO quercetin (4mg/ml), each given 40mg/kg	0.1% DMSO of Triptolide A (50ug/mL), given 500ug/kg per animal

Supplementary table 2. The different dose combination of triptolide and quercetin

The dose judgement for combined triptolide with quercetin in 96 wells plate					
TP 200nmol/L+QU 200nmol/L	TP 150nmol/L+QU 200nmol/L	TP 100nmol/L+QU 200nmol/L	TP 50nmol/L+QU 200nmol/L	TP 25nmol/L+QU 200nmol/L	None+QU 200nmol/L
TP 200nmol/L+QU 150nmol/L	TP 150nmol/L+QU 150nmol/L	TP 100nmol/L+QU 150nmol/L	TP 50nmol/L+QU 150nmol/L	TP 25nmol/L+QU 150nmol/L	None+QU 150nmol/L
TP 200nmol/L+QU 100nmol/L	TP 150nmol/L+QU 100nmol/L	TP 100nmol/L+QU 100nmol/L	TP 50nmol/L+QU 100nmol/L	TP 25nmol/L+QU 100nmol/L	None+QU 100nmol/L
TP 200nmol/L+QU 50nmol/L	TP 150nmol/L+QU 50nmol/L	TP 100nmol/L+QU 50nmol/L	TP 50nmol/L+U 50nmol/L	TP 25nmol/L+QU 50nmol/L	None+QU 50nmol/L
TP 200nmol/L+QU 25nmol/L	TP 150nmol/L+QU 25nmol/L	TP 100nmol/L+QU 25nmol/L	TP 50nmol/L+QU 25nmol/L	TP 25nmol/L+QU 25nmol/L	None+QU 25nmol/L
TP 200nmol/L+None	TP 150nmol/L+None	TP 100nmol/L+None	TP 50nmol/L+None	TP 25nmol/L+None	None+None

Note: The dose of each group is the concentration of the added drug divided by two, that is, the two drugs are 1:1 diluted with each other.

Supplementary table 3. the order of drug addition in transwell detection for cell migration and invasion

	steps	Control	QU	TP	TP+QU
lower chamber	1	None	300ul 200μmol/L QU containing 10% FBS	300ul 50nmol/L TP containing 10% FBS	300ul 50nmol/L TP containing 10% FBS
	2	600ul contains 10% FBS serum	300ul 10% FBS medium	300ul 10% FBS medium	300ul 200μmol/L QU containing 10% FBS
upper chamber	3	150ul serum containing 1% FBS	50ul 1% FBS medium	100ul 1% FBS medium	50ul 100nmol TP containing 1% FBS
	4	None	100ul 200μmol/L QU containing 1% FBS	50ul 100nmol TP containing 1% FBS	100ul 200μmol/L QU containing 1% FBS
	5	50ul 1×10^6 /L cell suspension	50ul 1×10^6 /L cell suspension	50ul 1×10^6 /L cell suspension	50ul 1×10^6 /L cell suspension

ID	Description	GeneRatio	BgRatio
hsa04115	p53 signaling pathway	3/72	73/8223
hsa01230	Biosynthesis of amino acids	3/72	75/8223
hsa04710	Circadian rhythm	2/72	34/8223
hsa04550	Signaling pathways regulating pluripotency of stem cells	4/72	143/8223
hsa04610	Complement and coagulation cascades	3/72	86/8223
hsa05224	Breast cancer	4/72	147/8223
hsa00250	Alanine, aspartate and glutamate metabolism	2/72	37/8223
hsa04512	ECM-receptor interaction	3/72	88/8223
hsa05222	Small cell lung cancer	3/72	92/8223
hsa04657	IL-17 signaling pathway	3/72	94/8223

pvalue	geneID	Count
0.02587	SESN2/GADD45A/PMAIP1	3
0.027743	CTH/ASNS/GPT2	3
0.035417	BHLHE41/CLOCK	2
0.036324	INHBE/FGFR3/ID1/WNT6	4
0.0393	MASP1/BDKRB2/C2	3
0.039576	FGF21/NOTCH3/GADD45A/WNT6	4
0.041349	ASNS/GPT2	2
0.041627	HMMR/ITGA2/LAMA4	3
0.046486	GADD45A/ITGA2/LAMA4	3
0.049016	FOSB/MAPK4/CCL2	3